Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information

v3.25.1
Segment Information
12 Months Ended
Dec. 31, 2024
Segment Information  
Segment Information

Note 10 – Segment Information

Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which discrete financial information is available that is evaluated regularly by the CODM to allocate resources and assess performance.

The Company operates in one reportable segment, immunotherapy and targeted oncology therapy, which includes all activities related to the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, including UNLOXCYT. The determination of a single reportable segment is consistent with the financial information regularly provided to the Company’s CODM, which is its chief executive officer, who reviews and evaluates net loss, as reported on the Company’s Statements of Operations, for purposes of assessing performance, making operating decisions, allocating resources and planning and forecasting for future periods. Net loss is also used to monitor budget versus actual results. The measure of segment assets is reported on the Company’s Balance Sheets as total assets.

For the years ended December 31, 2024 and 2023, the significant expense categories regularly provided to the CODM consisted of the following (in thousands):

    

For the year ended December 31,

2024

2023

Revenue - related party

$

41

$

103

Operating expenses:

 

  

 

  

Employee Expenses

 

8,624

 

7,285

Stock-based Compensation

 

15,252

 

2,897

Fortress Founder's Agreement and MSA Expenses

 

9,133

 

4,871

Manufacturing and Development Expenses

 

10,755

 

19,013

Clinical Expenses

 

3,901

 

6,981

Regulatory Expenses

 

334

 

3,615

License Fees

 

152

 

2,300

Legal & Accounting Expense

 

4,123

 

1,814

R&D Other Expense (1)

 

1,629

 

1,439

G&A Other Expense (2)

 

2,312

 

2,036

Total Operating Expenses

 

56,215

 

52,251

Other Segment Items (3)

(66)

301

Net Loss

$

(56,240)

$

(51,847)

(1) R&D Other Expense includes travel, consulting, and outside service expenses.

(2) G&A Other Expense includes travel, consulting, marketing, business development, investor relations and outside services expenses.

(3) Other Segment Items include interest income, foreign currency exchange loss, and gain (loss) on common stock warrant liabilities.